CD4 T cells in tumor immunity
- PMID: 15965712
- DOI: 10.1007/s00281-004-0193-z
CD4 T cells in tumor immunity
Abstract
T cell immunity is the key to protective immune responses against tumors. Traditionally, this function has been ascribed to CD8 T lymphocytes with cytotoxic activity, which are restricted by MHC class I molecules. In recent years the realization that CD4 T cells can also play a relevant role in protective anti-tumor responses has received growing attention. Here we will discuss the role of MHC class II-restricted T cells in response to, and in the regulation of, tumor antigens. Emphasis will be placed on four areas: (1) the role of CD4 T cell immunity in tumor protection in animal models and putative mode of action, (2) tumor antigens recognized by human CD4 T cells, (3) the cooperation between two CD4 T cells of different specificity as a new way to jump start the response against sub-immunogenic determinants of tumor antigens in a tolerant environment, and (4) the negative impact of regulatory CD4 T cells on anti-tumor T cell responses. By drawing attention to these four areas, it is our intention to provide the reader with a comprehensive view of issues of contemporary importance for this field, in the expectation that the information will help a better design of therapeutic cancer vaccines.
Similar articles
-
MHC class I TCR engineered anti-tumor CD4 T cells: implications for cancer immunotherapy.Endocr Metab Immune Disord Drug Targets. 2009 Dec;9(4):344-52. doi: 10.2174/187153009789839183. Endocr Metab Immune Disord Drug Targets. 2009. PMID: 19807670
-
The role of CD4+ T cell responses in antitumor immunity.Curr Opin Immunol. 1998 Oct;10(5):588-94. doi: 10.1016/s0952-7915(98)80228-8. Curr Opin Immunol. 1998. PMID: 9794842 Review.
-
MHC class II-restricted tumor antigens recognized by CD4+ T cells: new strategies for cancer vaccine design.J Immunother. 2001 May-Jun;24(3):195-204. J Immunother. 2001. PMID: 11394496 Review.
-
MHC class II restricted tumor antigens and the role of CD4+ T cells in cancer immunotherapy.Curr Opin Immunol. 1994 Oct;6(5):741-5. doi: 10.1016/0952-7915(94)90078-7. Curr Opin Immunol. 1994. PMID: 7826529 Review.
-
Aberrant Expression of MHC Class II in Melanoma Attracts Inflammatory Tumor-Specific CD4+ T- Cells, Which Dampen CD8+ T-cell Antitumor Reactivity.Cancer Res. 2015 Sep 15;75(18):3747-59. doi: 10.1158/0008-5472.CAN-14-2956. Epub 2015 Jul 16. Cancer Res. 2015. PMID: 26183926
Cited by
-
Depletion of CD4+ CD25+ regulatory T cells inhibits local tumour growth in a mouse model of B cell lymphoma.Clin Exp Immunol. 2008 May;152(2):381-7. doi: 10.1111/j.1365-2249.2008.03642.x. Epub 2008 Mar 12. Clin Exp Immunol. 2008. PMID: 18341610 Free PMC article.
-
Deficiency of AMPK in CD8+ T cells suppresses their anti-tumor function by inducing protein phosphatase-mediated cell death.Oncotarget. 2015 Apr 10;6(10):7944-58. doi: 10.18632/oncotarget.3501. Oncotarget. 2015. PMID: 25760243 Free PMC article.
-
Th9 cells promote antitumor immune responses in vivo.J Clin Invest. 2012 Nov;122(11):4160-71. doi: 10.1172/JCI65459. Epub 2012 Oct 15. J Clin Invest. 2012. PMID: 23064366 Free PMC article.
-
Lipid metabolism associated crosstalk: the bidirectional interaction between cancer cells and immune/stromal cells within the tumor microenvironment for prognostic insight.Cancer Cell Int. 2024 Aug 22;24(1):295. doi: 10.1186/s12935-024-03481-4. Cancer Cell Int. 2024. PMID: 39174964 Free PMC article. Review.
-
Expression of indoleamine 2, 3-dioxygenase and the recruitment of Foxp3-expressing regulatory T cells in the development and progression of uterine cervical cancer.Cancer Sci. 2007 Jun;98(6):874-81. doi: 10.1111/j.1349-7006.2007.00470.x. Epub 2007 Apr 13. Cancer Sci. 2007. PMID: 17433037 Free PMC article.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials